Global health teams from Geisel and its partner organizations held a symposium in Dar es Salaam in December to provide critical updates in TB care, prevention, and research. The event was the latest step in their 17-year history of working collaboratively to combat HIV-related TB in Tanzania.
Post Tagged with: "TB"
The Geisel School of Medicine has been awarded a 5-year, $1.5 million grant from the Fogarty International Center at the National Institutes of Health to support an infectious disease research and training program to combat HIV and tuberculosis (TB) within the newly established Infectious Disease Institute at Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam, Tanzania.
Investigators at Dartmouth’s Geisel School of Medicine announced that two new studies of DAR-901, their investigational vaccine against tuberculosis (TB), have moved it to the forefront of new vaccines in development for global control of this deadly infectious disease.
A collaborative of Dartmouth’s Geisel School of Medicine, Muhimbili University of Health and Allied Sciences in Tanzania, and Tokyo Medical and Dental University received $1.4 million from Japan’s Global Health Innovative Technology Fund to conduct a joint randomized clinical trial in Tanzania aimed at reducing the transmission of tuberculosis.
Dartmouth’s Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world’s deadliest diseases.